Efficacy and safety of chemotherapy combined with interstitial (125)I seed implantation brachytherapy in unresectable stage IIIa/IIIb non-small cell lung cancer.
- Author:
Shu-fa YANG
1
;
Xi-wen FAN
;
Guo-qing ZHANG
;
Li SHAN
Author Information
- Publication Type:Journal Article
- MeSH: Alopecia; etiology; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Brachytherapy; adverse effects; Carcinoma, Non-Small-Cell Lung; drug therapy; pathology; radiotherapy; Cisplatin; administration & dosage; Combined Modality Therapy; Deoxycytidine; administration & dosage; analogs & derivatives; Diarrhea; etiology; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; adverse effects; therapeutic use; Leukopenia; etiology; Lung Neoplasms; drug therapy; pathology; radiotherapy; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vinblastine; administration & dosage; analogs & derivatives; Vomiting; etiology
- From: Chinese Journal of Oncology 2010;32(8):626-629
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and toxicity of chemotherapy combined with insterstitial (125)I seed implantation brachytherapy in unresectable staged IIIa/IIIb non-small cell lung cancer.
METHODSSeventy six patients with staged IIIa/IIIb non-small cell lung cancer were included in this study. Among them 37 cases were of the study group, treated with NP/GP scheme synchronization chemotherapy combined with (125)I seed implantation brachytherapy, while 39 cases in the control group were given NP/GP scheme chemotherapy. The cumulative survival time and median survival time of the two groups were compared by Kaplan-Meier analysis. The difference of mean survival time between the two groups was analyzed by log-rank method.
RESULTSThe study group and the control group achieved a total response rate of 56.8% and 30.8%, local control rate of 78.4% and 56.4%, respectively, showing a statistically significant difference (P < 0.05). The 1-year survival rates of the study group and control group were 66.7% and 45.3%, and the median survival times 15.4 and 11.5 months, respectively, with a significant difference between the 2 groups (P < 0.05). The total chemotherapy toxicity rate of the two groups showed no significant difference (P > 0.05).
CONCLUSIONThe (125)I seed implantation brachytherapy combined with concurrent chemotherapy shows a low complication rate, acceptable toxicity, and good therapeutic effectiveness, and is an effective and satisfactory therapeutic modality in the management of locally advanced non-small cell lung cancer.
